A carregar...
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
HER2 amplification is seen in up to 20% of breast cancers and is associated with an aggressive phenotype. Trastuzumab, a monoclonal antibody to HER2, accrues significant clinical benefit in the metastatic and adjuvant settings. However, some patients suffer disease recurrence despite adjuvant trastu...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3092522/ https://ncbi.nlm.nih.gov/pubmed/21342044 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/era.10.226 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|